Effect of 7-nitroindazole on tolerance to morphine, U-50,488H and [D- Pen2, D-Pen5]enkephalin in mice

Peptides

Volumn 18, Issue 6, 1997, Pages 797-800

  Bhargava, Hemendra N ^a   Cao, Ying Jun ^a   Zhao, Guo Min ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

7 Nitroindazole; D Pen2, D Pen5 Enkephalin; Antinociception; Mice; Morphine; Nitric oxide synthase; Tolerance; U 50,488H

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 7 NITROINDAZOLE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MORPHINE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANALGESIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ANALGESICS, OPIOID; ANIMALS; DRUG TOLERANCE; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; ENZYME INHIBITORS; INDAZOLES; MALE; MICE; MORPHINE; NITRIC OXIDE SYNTHASE; NOCICEPTORS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA;

EID: 0030865079     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00021-1     Document Type: Article

References (24)

1. Babbedge R. C., Bland-Ward P. A., Hart S. L., Moore P. K. Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br. J. Pharmacol. 110:1993;225-228.
2. Babey A. M., Kolesnikov Y., Cheng J., Inturrisi C. E., Trifilletti R. R., Pasternak G. W. Nitric oxide and opioid tolerance. Neuropharmacology. 33:1994;1463-1470.
3. Bhargava H. N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self-administrative behavior. Pharmacol. Rev. 46:1994;293-324.
4. Bhargava H. N. Nitric oxide synthase inhibition blocks tolerance to the analgesic action of U-50,488H, a κ -opioid receptor agonist in the rat. Pharmacology. 48:1994;234-241.
5. Bhargava H. N. Attenuation of tolerance to and physical dependence on morphine in the rat by inhibition of nitric oxide synthase. Gen. Pharmacol. 26:1995;1049-1053.
6. Bhargava, H. N.; Kumar, S. Effect of multipleinjections of κ -opioid receptor agonist on the nitric oxidesynthase activity in the brain regions and spinal cord of mice. Gen. Pharmacol. 1997 (in press).
7. Bhargava H. N., Thorat S. N. Evidence for a role of nitric oxide of the central nervous system in morphine abstinence syndrome. Pharmacology. 52:1996;86-91.
8. 5]enkephalin and morphine in the mouse. Neuropeptides. 30:1996;219-223.
9. Bredt D. S., Hwang P. M., Snyder S. H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 347:1990;768-770.
10. Bredt D. S., Snyder S. H. Nitric oxide, a novel neuronal messenger. Neuron. 8:1992;3-11.
11. Cappendijk S. L. T., Duval S. Y., deVries R., Dzoljic M. R. Comparative study of normotensive and hypertensive nitric oxide synthase inhibitors on morphine withdrawal syndrome in rats. Neurosci. Lett. 183:1995;67-70.
12. Garthwaite J. Glutamic acid, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci. 14:1991;60-67.
13. Haley T. J., McCormick W. G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 12:1957;12-15.
14. Knowles R., Palacios M., Palmer R. M. J., Moncada S. Formation of nitric oxide from L-arginine in the central nervous system: A transduction mechanism for stimulation of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. USA. 86:1989;5159-5162.
15. Kolesnikov Y. A., Pick C. G., Ciszewska G., Pasternak G. W. Blockade of tolerance to morphine but not to κ -opioids by nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. USA. 90:1993;5162-5166.
16. Kumar, S.; Bhargava, H. N. Time course of the changesin central nitric oxide synthase activity following chronictreatment with morphine in the mouse: Reversal by naltrexone. Gen. Pharmacol. 1997 (in press).
17. 2] deltorphin II in mice: Evidence of δ -receptor subtypes. J. Pharmacol. Exp. Ther. 258:1991;583-587.
18. Moncada S., Higgs E. A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Invest. 21:1991;361-374.
19. Moore P. K., Wallace P., Gaffen L. A., Hart S. L., Babbedge R. C. Characterization of the novel nitric oxide synthase inhibitor 7-nitroindazole and related indazoles: Antinociceptive and cardiovascular effects. Br. J. Pharmacol. 110:1993;219-224.
20. Nathan C., Xie Q. W. Nitric oxide synthases: Roles, tolls, and controls. Cell. 78:1994;915-918.
21. G-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice. Brain Res. 642:1994;153-159.
22. Thorat S. N., Reddy P. L., Bhargava H. N. Evidence for the role of nitric oxide in kappa opiate tolerance in mice. Brain Res. 621:1993;171-174.
23. Vaupel D. B., Kimes A. S., London E. D. Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology. 118:1995;361-368.
24. 2 -opioid receptor agonist in mice. Peptides. 17:1996;619-623.